Stocktoria
CDT Equity Inc. CDT
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2022-02-03
CDT Equity Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| R&D expense | $5.1M | $3.4M | $90,000 | $37,000 |
| Operating income | -$36.8M | -$15.4M | -$5.3M | -$3.2M |
| Interest expense | $200,000 | $32,000 | — | $100,000 |
| Income tax | — | — | — | $374,862 |
| Net income | -$39.2M | -$17.8M | -$535,000 | -$4.9M |
| EPS (diluted) | $-1177.89 | $-61598.62 | $-8.92 | $-0.13 |
| Operating cash flow | -$15.6M | -$9.7M | -$7.7M | -$2.3M |
| Free cash flow | — | -$9.7M | — | — |
| Cash & equivalents | $1.5M | $554,000 | $4.2M | $345,777 |
| Total assets | $5.7M | $4.2M | $7.2M | $5,000 |
| Total liabilities | $12.8M | $11.0M | $7.7M | $10.1M |
| Shareholders' equity | -$7.2M | -$6.8M | -$457,000 | -$10.1M |
Source: SEC EDGAR filings · CIK 0001896212 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.